Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212
J. Clin. Invest. J. Ludovic Croxford, et al. 111:1231 doi:10.1172/JCI17652 [Go to this article.]

Figure 2
Cannabinoid treatment increases the susceptibility of mice to TMEV infection and is not cytotoxic to splenocytes. R(+)WIN55,212 treatment of mice at the time of infection (a) (black bars) showed a significant increase in CNS virus titers compared with either S(–)WIN55,212 (gray bars) or untreated (white bars) TMEV-infected mice. Virus titers were not different from controls in mice treated with R(+)WIN55,212 at the onset of disease (b). *Significant increase in viral load in R(+)WIN55,212-treated mice compared with either S(–)WIN55,212 or untreated TMEV mice (P < 0.05). No PFUs were observed in naive mice. R(+)WIN55,212 treatment has no cytotoxic effect, as measured by FACS analysis of splenic CD4⁺, CD8⁺, B220⁺, and CD4⁺CD25⁺ lymphocytes, and F4/80⁺ macrophage populations compared with S(–)WIN55,212 or naive mice (c). Results are expressed as the mean total number of cells (n = 3 per group) ± SEM.